Vertex Pharmaceuticals Shares Outstanding History (VRTX)
Vertex Pharmaceuticals reported 254.0M shares outstanding at the end of fiscal 2025.
View full Vertex Pharmaceuticals company overviewVertex Pharmaceuticals annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 254.0M | −2.9M | −1.15% |
| 2024 | 2024-12-31 | 256.9M | −754,839 | −0.29% |
| 2023 | 2023-12-31 | 257.7M | 683,593 | +0.27% |
| 2022 | 2022-12-31 | 257.0M | 2.5M | +1.00% |
| 2021 | 2021-12-31 | 254.5M | −5.4M | −2.08% |
| 2020 | 2020-12-31 | 259.9M | 896,549 | +0.35% |
| 2019 | 2019-12-31 | 259.0M | 3.8M | +1.50% |
| 2018 | 2018-12-31 | 255.2M | 1.9M | +0.76% |
| 2017 | 2017-12-31 | 253.3M | 5.0M | +1.99% |
| 2016 | 2016-12-31 | 248.3M | 2.0M | +0.81% |
| 2015 | 2015-12-31 | 246.3M | 4.5M | +1.88% |
| 2014 | 2014-12-31 | 241.8M | 8.0M | +3.41% |
| 2013 | 2013-12-31 | 233.8M | 16.5M | +7.59% |
| 2012 | 2012-12-31 | 217.3M | 8.0M | +3.81% |
| 2011 | 2011-12-31 | 209.3M | 5.8M | +2.84% |
| 2010 | 2010-12-31 | 203.5M | 3.6M | +1.78% |
| 2009 | 2009-12-31 | 200.0M | — | — |
Vertex Pharmaceuticals quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 253.3M | −2.9M | −1.15% |
| Q1 2026 | 2026-03-31 | 254.2M | −2.8M | −1.09% |
| Q4 2025 | 2025-12-31 | 254.0M | −2.9M | −1.15% |
| Q3 2025 | 2025-09-30 | 254.0M | −3.8M | −1.47% |
| Q2 2025 | 2025-06-30 | 256.3M | −1.7M | −0.67% |
| Q1 2025 | 2025-03-31 | 257.0M | −1.3M | −0.51% |
| Q4 2024 | 2024-12-31 | 256.9M | −754,839 | −0.29% |
| Q3 2024 | 2024-09-30 | 257.7M | −88,909 | −0.03% |
| Q2 2024 | 2024-06-30 | 258.0M | 222,653 | +0.09% |
| Q1 2024 | 2024-03-31 | 258.3M | 786,488 | +0.31% |
| Q4 2023 | 2023-12-31 | 257.7M | 683,593 | +0.27% |
| Q3 2023 | 2023-09-30 | 257.8M | 1.2M | +0.46% |
| Q2 2023 | 2023-06-30 | 257.8M | 1.8M | +0.69% |
| Q1 2023 | 2023-03-31 | 257.5M | 1.9M | +0.76% |
| Q4 2022 | 2022-12-31 | 257.0M | 2.5M | +1.00% |
| Q3 2022 | 2022-09-30 | 256.6M | 439,737 | +0.17% |
| Q2 2022 | 2022-06-30 | 256.0M | −3.1M | −1.19% |
| Q1 2022 | 2022-03-31 | 255.6M | −3.3M | −1.26% |
| Q4 2021 | 2021-12-31 | 254.5M | −5.4M | −2.08% |
| Q3 2021 | 2021-09-30 | 256.2M | −4.0M | −1.53% |
| Q2 2021 | 2021-06-30 | 259.1M | −1.0M | −0.39% |
| Q1 2021 | 2021-03-31 | 258.8M | −250,000 | −0.10% |
| Q4 2020 | 2020-12-31 | 259.9M | 897,000 | +0.35% |
| Q3 2020 | 2020-09-30 | 260.2M | 2.9M | +1.13% |
| Q2 2020 | 2020-06-30 | 260.1M | 3.5M | +1.35% |
| Q1 2020 | 2020-03-31 | 259.1M | 2.7M | +1.06% |
| Q4 2019 | 2019-12-31 | 259.0M | 3.8M | +1.50% |
| Q3 2019 | 2019-09-30 | 257.3M | 1.7M | +0.65% |
| Q2 2019 | 2019-06-30 | 256.7M | 1.8M | +0.70% |
| Q1 2019 | 2019-03-31 | 256.4M | 1.5M | +0.58% |
| Q4 2018 · Dec 31 | 2018-12-31 | 255.2M | 1.9M | +0.76% |
| Q3 2018 | 2018-09-30 | 255.6M | 2.9M | +1.16% |
| Q2 2018 | 2018-06-30 | 254.9M | 4.1M | +1.64% |
| Q1 2018 | 2018-03-31 | 254.9M | 6.0M | +2.40% |
| Q4 2017 · Dec 31 | 2017-12-31 | 253.3M | 5.0M | +1.99% |
| Q3 2017 | 2017-09-30 | 252.7M | 4.7M | +1.88% |
| Q2 2017 | 2017-06-30 | 250.8M | 3.1M | +1.24% |
| Q1 2017 | 2017-03-31 | 248.9M | 1.6M | +0.65% |
| Q4 2016 | 2016-12-31 | 248.3M | 2.0M | +0.81% |
| Q3 2016 | 2016-09-30 | 248.0M | 2.4M | +0.97% |
| Q2 2016 | 2016-06-30 | 247.7M | 3.4M | +1.38% |
| Q1 2016 | 2016-03-31 | 247.3M | 3.7M | +1.52% |
| Q4 2015 | 2015-12-31 | 246.3M | 4.5M | +1.88% |
| Q3 2015 | 2015-09-30 | 245.6M | 5.4M | +2.25% |
| Q2 2015 | 2015-06-30 | 244.3M | 7.0M | +2.95% |
| Q1 2015 | 2015-03-31 | 243.6M | 7.4M | +3.12% |
| Q4 2014 | 2014-12-31 | 241.8M | 8.2M | +3.50% |
| Q3 2014 | 2014-09-30 | 240.2M | 6.6M | +2.85% |
| Q2 2014 | 2014-06-30 | 237.3M | 18.7M | +8.54% |
| Q1 2014 | 2014-03-31 | 236.2M | 18.9M | +8.70% |
| Q4 2013 | 2013-12-31 | 233.6M | 17.3M | +7.97% |
| Q3 2013 | 2013-09-30 | 233.6M | 18.2M | +8.43% |
| Q1 2013 | 2013-03-31 | 218.7M | 7.8M | +3.69% |
| Q4 2012 | 2012-12-31 | 217.3M | 8.0M | +3.81% |
| Q3 2012 | 2012-09-30 | 216.3M | 7.9M | +3.78% |
| Q2 2012 | 2012-06-30 | 215.4M | 8.0M | +3.84% |
| Q1 2012 | 2012-03-31 | 210.9M | 5.4M | +2.63% |
| Q4 2011 | 2011-12-31 | 209.3M | 5.8M | +2.84% |
| Q3 2011 | 2011-09-30 | 208.5M | 5.4M | +2.64% |
| Q2 2011 | 2011-06-30 | 207.5M | 4.9M | +2.44% |
| Q1 2011 | 2011-03-31 | 205.5M | 3.3M | +1.65% |
| Q4 2010 | 2010-12-31 | 203.5M | 3.6M | +1.78% |
| Q3 2010 | 2010-09-30 | 203.1M | — | — |
| Q2 2010 | 2010-06-30 | 202.5M | — | — |
| Q1 2010 | 2010-03-31 | 202.1M | — | — |
| Q4 2009 | 2009-12-31 | 200.0M | — | — |
Vertex Pharmaceuticals shares outstanding trends
Over the last five reported fiscal years, Vertex Pharmaceuticals's shares outstanding moved from 259.9M to 254.0M, a change of −5.9M. The latest reported quarter, Q2 2026, shows 253.3M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vertex Pharmaceuticals filings at SEC.gov ↗